第二十四届长城国际心脏病学会议暨亚太心脏大会2013

2013年ACCF/AHA ST段抬高型心肌梗死指南

   2013-08-13
字体大小:
The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist physicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools.
 
The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly produced guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guidelines (Task Force), charged with developing, updating, and revising practice guidelines for cardiovascular diseases and procedures, directs and oversees this effort. Writing committees are charged with regularly reviewing and evaluating all available evidence to develop balanced, patient-centric recommendations for clinical practice.
 
Experts in the subject under consideration are selected by the ACCF and AHA to examine subject-specific data and write guidelines in partnership with representatives from other medical organizations and specialty groups. Writing committees are asked to perform a formal literature review; weigh the strength of evidence for or against particular tests, treatments, or procedures; and include estimates of expected outcomes where such data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that may influence the choice of tests or therapies are considered. When available, information from studies on cost is considered, but data on efficacy and outcomes constitute the primary basis for the recommendations contained herein.

编辑: 长江    来源:丁香园

网友评论

男,1946年7月生于河南开封。中国共产党党员。主任医师、教授、博士生导师,国家和北京市突出贡献专家、卫生部健康教育首席专家,国家重点学科心血管内科负责人,享受政府专家津贴。

中国国际科技会议中心

长城国际心脏病学会议组委会

亚太心脏联盟

首都医科大学心脏病学系

中华医学会心血管病学分会

中国医师协会心血管内科医师分会

中国康复医学会心血管病专业委员会

中国老年学学会心脑血管病专业委员会

中国生物医学工程学会心律分会

查看更多